Thought Leadership

When is Longitudinal Data Important to Life Sciences Companies?

September 2019

Moving Toward More Targeted Treatments in Specialty Care

The Complexities of Immunotherapy

3 Reasons Why Today’s Healthcare Data May Be Limiting Your View of Your Drug’s Market Potential

The Evolution of Cancer

Delivering Differentiated Clinical Education to Practices

Understanding Data's Value to Specialty Products

Rapid Advancements in Immunotherapy

Medication Adherence – What Data is Available to Provide Insight into Non-Compliance?

Pharmaceutical Companies Need Data to Improve Product Access and Utilization

The Changing Business Model

HHS Institutes Ruling for More Transparency in Clinical Trials

What Does Interoperability Mean to Patient Health?